Evidence map›Paper›PMID 31351487›Full record

ArticleAIDS research and therapy2019

Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir.

Laura Campogiani, Carlotta Cerva, Gaetano Maffongelli, Elisabetta Teti, Livio Pupo, Sara Vaccarini, Maria Cantonetti, Alfredo Pennica, Massimo Andreoni, Loredana Sarmati

Open access · goldAbstract readCase Reports
In one paragraph

Article in AIDS research and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. A Critical Role for Epstein-Barr Virus in Primary Effusion Lymphoma.Current topics in microbiology and immunology · 2025
    Article
  2. Article
  3. HIV/AIDS Associated Lymphoma: Review.Blood and lymphatic cancer : targets and therapy · 2022
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Laura CampogianiClinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy.
Carlotta CervaClinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy.
Gaetano MaffongelliClinical Infectious Diseases, Belcolle Hospital, Viterbo, Italy.
Elisabetta TetiClinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy.
Livio PupoDepartment of Hematology, Tor Vergata University, Rome, Italy.
Sara VaccariniDepartment of Hematology, Tor Vergata University, Rome, Italy.
Maria CantonettiDepartment of Hematology, Tor Vergata University, Rome, Italy.
Alfredo PennicaClinical Infectious Disease, Sant´Andrea Hospital, Rome, Italy.
Massimo AndreoniClinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy.
Loredana SarmatiClinical Infectious Disease, Department of System Medicine, Tor Vergata University, Rome, Italy. sarmati@med.uniroma2.it.ORCID 0000-0003-1452-0333
University of Rome Tor Vergata · ITCTO Andrea Alesini · ITOspedale di Belcolle · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman herpes virus 8 (HHV8) is the causative agent of Kaposi's sarcoma and has been associated with an increasing number of hematologic diseases such as primary effusion lymphoma (PEL) (both classic and extracavitary form), multicentric Castleman disease and the germinotropic lymphoproliferative disorder. PEL is a rare B cell non-Hodgkin lymphoma that primarily affects immunocompromised patients; aggressive chemotherapy and antiretroviral therapy (ART) with protease inhibitors have been used, with poor results. We present a case of extracavitary PEL in an HIV-infected patient, regressed after ART initiation. CASE PRESENTATION: A 42-year-old male was admitted to the emergency room because of several months of malaise, fever and progressive deterioration of the general conditions. On physical examination soft non-painful subcutaneous masses were palpable at retronuchal, retroauricolar and thoracic regions. HIV serology resulted positive: HIV plasma viremia was 782,270 copies/mL, CD4 103 cells/mL. The excision of one of the masses, metabolically active at a positron emission tomography (PET-CT) scan, revealed an HHV8-related extracavitary PEL. HHV8 plasma viremia was 44,826 copies/mL. ART with tenofovir alafenamide/emtricitabine/dolutegravir was started together with ganciclovir for cytomegalovirus chorioretinitis. The progressive disappearance of the masses was seen after 6 weeks of ART, and a PET-CT scan resulted completely negative at 3 months. After 19 months of ART the patient was in remission of PEL, HIV viremia was undetectable (< 20 copies/mL), CD4 count was 766 cells/mL and HHV8 viremia was undetectable.

conclusionsIn this clinical case, the complete regression of PEL has been achieved after the immune recovery, as a consequence of ART introduction, without chemotherapy. It cannot be excluded that ganciclovir, used for the treatment of CMV chorioretinitis, may have contributed to the control of HHV8 replication. Whether to try or not a conservative approach in HIV-infected PEL patients must be carefully evaluated, considering the patient's characteristics and the prognostic factors.

Indexed as

AdultAnti-Retroviral AgentsDolutegravirHerpesviridae InfectionsHerpesvirus 8, HumanHeterocyclic Compounds, 3-RingHIV InfectionsHumansLymphoma, Primary EffusionMaleOxazinesPiperazinesPositron-Emission TomographyPyridonesRemission InductionAnti-Retroviral AgentsDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesDolutegravirHHV8Primary effusion lymphoma

Identifiers

PMID31351487
PMCPMC6660660
OpenAlexW2965316509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.